A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants
← catalyst calendarSponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
16actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-17 | actual | When the study began enrolling |
| Primary completion | 2025-02-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-24 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19
Interventions
- Drug: S-892216
- Drug: Carbamazepine — also filed as Tegretol
Primary outcomes
what the primary-completion date above is the date OFPlasma Concentration of S-892216
measured Days 1 and 35 (2 hours predose, 30 minutes to 144 hours postdose)
Time to Maximum Plasma Concentration (Tmax) of S-892216
measured Days 1 and 35 (2 hours predose, 30 minutes to 144 hours postdose)
Plasma Concentration of Carbamazepine
measured Day 35 (2 hours predose, 30 minutes to 24 hours postdose)
Tmax of Carbamazepine
measured Day 35 (2 hours predose, 30 minutes to 24 hours postdose)
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed